Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChimeriVax-JE in Thai Children
NCT00621764Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2008
- Primary completion
- Dec 2009
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (4 arms), sponsored by Sanofi. Primary endpoint: Number of Participants With Solicited Injection Site and Systemic Reactions. Started Mar 2008; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00621764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621764.